New migraine drug tested on 3,000 patients in Real-Life settings
NCT ID NCT06439628
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how well Rimegepant works for treating migraine attacks in everyday life. About 3,000 adults with migraine will take the drug as prescribed by their doctor and report their pain levels, relief timing, and satisfaction. The goal is to see if Rimegepant helps reduce pain and improve daily function over 12 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MIGRAINE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Chinese PLA General Hospital
Beijing, Beijing Municipality, China
-
Peking University People's Hospital
Beijing, Beijing Municipality, China
-
The Second Affiliated Hospital Zhejiang University School of Medicine
Hangzhou, Zhenjiang, China